gdc

Web Exclusives

Leukemia
Web Exclusives – June 23, 2020
Long-term results of a pivotal trial of acalabrutinib verify that it is effective and safe as first-line therapy for patients with chronic lymphocytic leukemia.
Leukemia
Web Exclusives – June 23, 2020
According to findings from a large clinical trial, the combination of ibrutinib and ublituximab is effective in treating patients with chronic lymphocytic leukemia.
Leukemia
Web Exclusives – June 23, 2020
The ASCEND trial confirmed that acalabrutinib, a next-generation targeted treatment, is more effective than traditional chemoimmunotherapy in patients with relapsed chronic lymphocytic leukemia.
Leukemia
Web Exclusives – June 23, 2020
Recently reported data show that fixed-duration treatment with venetoclax and obinutuzumab for 12 months is effective and tolerable in some patients with chronic lymphocytic leukemia.
Leukemia
Web Exclusives – June 23, 2020
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who require systemic therapy have a new chemotherapy-free combination regimen to consider.
Leukemia
Web Exclusives – May 27, 2020
The chemotherapy-free combination of venetoclax plus obinutuzumab has shown efficacy and tolerability in older patients with chronic lymphocytic leukemia. Adding acalabrutinib, a new targeted agent, may enhance the clinical benefits of this regimen, according to results of a clinical trial.
Leukemia
Web Exclusives – May 27, 2020
Cancer specialists are now able to use a new scoring system to decide when to start treatment for patients who have been diagnosed with chronic lymphocytic leukemia.
Leukemia
Web Exclusives – May 27, 2020
Alliance A041702 is a large clinical trial that is exploring whether adding venetoclax to the combination of ibrutinib and obinutuzumab can improve outcomes in patients with chronic lymphocytic leukemia.
Leukemia
Web Exclusives – May 27, 2020
According to results from a recent study, patients with chronic lymphocytic leukemia are more likely to survive for longer time periods if their posttreatment tests show no evidence of residual disease.
Leukemia
Web Exclusives – May 27, 2020
Pharmacists who specialize in managing medications for people with cancer offer unique services and support, especially for patients who are treated with targeted agents.
Page 1 of 14
Results 1 - 10 of 135

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country